Inventiva S.A. (IVA)
NASDAQ: IVA · IEX Real-Time Price · USD
2.600
+0.050 (1.96%)
Jul 19, 2024, 2:06 PM EDT - Market open

Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases.

Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Inventiva S.A.
Inventiva logo
Country France
Founded 2011
IPO Date Jul 10, 2020
Industry Biotechnology
Sector Healthcare
Employees 123
CEO Frederic Cren

Contact Details

Address:
50 Rue De Dijon
Daix, I0 21121
France
Phone 33380447500
Website inventivapharma.com

Stock Details

Ticker Symbol IVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
IPO Price $14.40
CIK Code 0001756594
CUSIP Number 46124U107
ISIN Number US46124U1079
SIC Code 2834

Key Executives

Name Position
Frederic Cren Co-Founder, Chief Executive Officer and Chairman
Dr. Pierre Broqua Ph.D. Co-Founder, Chief Scientific Officer, Deputy Chief Executive Officer and Director
Jean Volatier Deputy GM and Chief Financial Officer
Alice Roudot-Ketelers Pharm.D. Chief Operating Officer
Eric Duranson L.L.M. General Counsel
Nathalie Harroy Head of Human Resources
Dr. Michael Cooreman Chief Medical Officer
Pascaline Clerc Ph.D. Executive Vice President of Strategy and Corporate Affairs

Latest SEC Filings

Date Type Title
Jul 18, 2024 6-K Report of foreign issuer
Jul 5, 2024 6-K Report of foreign issuer
Jun 21, 2024 6-K Report of foreign issuer
Jun 21, 2024 6-K Report of foreign issuer
Jun 5, 2024 6-K Report of foreign issuer
May 30, 2024 6-K Report of foreign issuer
May 30, 2024 6-K Report of foreign issuer
May 21, 2024 6-K Report of foreign issuer
May 16, 2024 6-K Report of foreign issuer
May 13, 2024 6-K Report of foreign issuer